Antisense Pharma’s SAPPHIRE Phase III trial evaluating trabedersen approved by Health Canada Research to examine trabedersen vs cialisisverige.com . Current standard chemotherapy in sufferers with recurrent or refractory anaplastic astrocytoma The biopharmaceutical firm Antisense Pharma GmbH has announced today that it has received the approval by Health Canada for its pivotal Stage III scientific trial SAPPHIRE in sufferers with recurrent or refractory anaplastic astrocytoma. The SAPPHIRE research is definitely a randomized, active-controlled, clinical trial designed to confirm the efficacy and basic safety of the investigational medication trabedersen , observed in previous clinical research.
The benefit of an off-the-shelf, biologic device is it avoids the weakening of the patient by firmly taking their own tissue. .. Aperion Biologics receives CE Mark approval for Z-Lig ACLR device Aperion Biologics, Inc. Aperion conducted a potential, randomized, controlled clinical trial in South and Europe Africa that demonstrated biological acceptance of its bioengineered porcine tendons, re-establishment of knee balance, and remodeling over time into the individual's have human ligament. U.S. Over 600,000 ACL reconstruction surgeries are performed around the globe annually, using the individual's own cells or cadaver tissue .